Domača stranSGEN • BMV
add
Seagen
Prejšnji trg. dan.
3.711,48 $
Letni razpon
3.711,48 $ - 3.711,48 $
Tržna kapitalizacija
43,15 mrd. USD
Razm. P/E
-
Dividendna donosnost
-
Borzne novice
Finančni podatki
Izkaz poslovnega izida
Prihodek
Čisti dohodek
(USD) | sep. 2023info | Sprememba L/L |
---|---|---|
Prihodek | 648,65 mio. | 27,11 % |
Stroški poslovanja | 262,69 mio. | 24,86 % |
Čisti dohodek | −215,79 mio. | −13,09 % |
Čista dobičkovnost prihodkov | −33,27 | 11,02 % |
Earnings per share | −1,15 | −11,65 % |
EBITDA | −209,33 mio. | −19,47 % |
Efektivna davčna stopnja | 0,26 % | — |
Bilanca stanja
Skupna sredstva
Skupne obveznosti
(USD) | sep. 2023info | Sprememba L/L |
---|---|---|
Denar. in kratkor. naložbe | 1,24 mrd. | −29,86 % |
Skupna sredstva | 3,63 mrd. | 0,42 % |
Skupne obveznosti | 1,08 mrd. | 35,94 % |
Celoten lastniški kapital | 2,55 mrd. | — |
Shares outstanding | 188,66 mio. | — |
Razmerje P/B | 274,52 | — |
Donosnost sredstev | −16,01 % | — |
Donosnost kapitala | −21,12 % | — |
Denarni tok
Neto sprememba denarnih sredstev
(USD) | sep. 2023info | Sprememba L/L |
---|---|---|
Čisti dohodek | −215,79 mio. | −13,09 % |
Denar iz dejavnosti | −35,82 mio. | 58,21 % |
Denar iz naložb | 142,49 mio. | 119,31 % |
Denar iz financiranja | 15,52 mio. | −15,59 % |
Neto sprememba denarnih sredstev | 119,90 mio. | 1.958,05 % |
Prost denarni tok | 71,52 mio. | 1.141,10 % |
Vizitka
Seagen Inc. is an American biotechnology company focused on developing and commercializing innovative, empowered monoclonal antibody-based therapies for the treatment of cancer. The company, headquartered in Bothell, Washington, is the industry leader in antibody-drug conjugates or ADCs, a technology designed to harness the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells. Antibody-drug conjugates are intended to spare non-targeted cells and thus reduce many of the toxic effects of traditional chemotherapy, while potentially enhancing antitumor activity.
The company's flagship product Adcetris is commercially available for four indications in more than 65 countries, including the U.S., Canada, Japan and members of the European Union.
To expand on the clinical opportunities of brentuximab vedotin, Seattle Genetics is conducting a broad clinical development program
to evaluate its therapeutic potential in earlier lines of its approved indications as well as in a range of other lymphoma and non-lymphoma settings. The company is jointly developing brentuximab vedotin in collaboration with Takeda Pharmaceutical Company. Wikipedia
Generalni direktor
Datum ustanovitve
15. jul. 1997
Sedež organizacije
Spletno mesto
Zaposleni
3.256